Overslaan en naar de inhoud gaan

Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks

Operational updates

Pharming Group N.V. today announced that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (“FDA”) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (“HAE”).

Lees meer

Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant

Operational updates

Pharming Group N.V. today announces that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).

Lees meer

Filters

  • Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren